NKp44L: A new tool for fighting cancer

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Vieillard, Vincent ^a   Baychelier, Florence ^a   Debré, Patrice ^a  

^a Assistance publique Hôpitaux de Paris   (France)

Author keywords

Immunotherapy; MLL5; Natural cytotoxicity receptors; Natural killer cells; NKp44; NKp44L; Tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MIXED LINEAGE LEUKEMIA PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NKP44L; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PROTEIN MLL5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL STRESS; CELL SURFACE; CELL TRANSFORMATION; HUMAN; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN EXPRESSION;

EID: 84899081599     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27988     Document Type: Article

References (10)

1. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi. org/10.1016/S0140-6736(00)03231-1.
2. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12:239-52; PMID:22437937; http://dx.doi.org/10.1038/nri3174.
3. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187:2065-72; PMID:9625766; http://dx.doi. org/10.1084/jem.187.12.2065.
4. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/annurev-immunol-032712-095951.
5. Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2013; In press; PMID:24366519; http://dx.doi. org/10.1038/icb.2013.98.
6. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debré P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 2013; 122:2935-42; PMID:23958951; http://dx.doi.org/10.1182/blood-2013-03-489054.
7. Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene 2002; 21:4849-54; PMID:12101424; http://dx.doi.org/10.1038/sj.onc.1205615.
8. Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, Morgan M, Bomm K, Göhring G, Lübbert M, et al. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol 2011; 29:682-9; PMID:21205756; http://dx.doi.org/10.1200/JCO.2010.31.1118.
9. Yew CW, Lee P, Chan WK, Lim VK, Tay SK, Tan TM, Deng LW. A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers. Cancer Res 2011; 71:6696-707; PMID:21908553; http://dx.doi. org/10.1158/0008-5472.CAN-11-1271.
10. Baychelier F, Vieillard V. The Modulation of the Cell-Cycle: A Sentinel to Alert the NK Cells of Dangers. Front Immunol 2013; 4:325; PMID:24109484; http://dx.doi.org/10.3389/fimmu.2013.00325.